Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma

Author(s):  
Natsuru Sudo ◽  
Hiroshi Ichikawa ◽  
Yusuke Muneoka ◽  
Takaaki Hanyu ◽  
Yosuke Kano ◽  
...  
2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 13-13
Author(s):  
Hiroshi Ichikawa ◽  
Natsuru Sudo ◽  
Shin-Ichi Kosugi ◽  
Takaaki Hanyu ◽  
Takashi Ishikawa ◽  
...  

Abstract Background The 8th edition of the American Joint Committee on Cancer staging (AJCC-8th) of esophageal cancer presents independent stage grouping for patients who underwent neoadjuvant therapy followed by esophagectomy (ypTNM). The aim of this study is to elucidate the clinical utility of ypTNM stage grouping in Japanese patients with esophageal squamous cell carcinoma (ESCC). Methods A total of 146 patients (121 men and 25 women, with a median age of 65 years) who underwent curative esophagectomy following neoadjuvant chemotherapy with cisplatin and 5-fluorouracil (CF) for ESCC between 2005 and 2011 were enrolled in this retrospective study. We compared the distribution of patients and disease-specific survival after esophagectomy (DSS) stratified by ypStage between AJCC-7th and 8th. Additionally, we evaluated the association between clinicopathological features including ypStage in AJCC-8th and DSS. Results The number of patients classified into ypStage 0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV was 5/1/14/11/35/40/18/18/4 in AJCC-7th, and that classified into ypStage I/II/IIIA/IIIB/IVA/IVB was 27/18/21/58/18/4 in AJCC-8th. According to the revision from AJCC-7th to 8th, ypStage of 85 and 7 patients was up- and down-graded, respectively. Up-grading of ypStage was observed in 83% of patients with ypT4 tumor and in 78% of patients with ypN1–3. The 5-year DSS of ypStage 0/IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV was 100/100/93/91/75/62/50/28/50% in AJCC-7th, and that of ypStage I/II/IIIA/IIIB/IVA/IVB was 96/83/68/58/28/50% in AJCC-8th. The 5-year DSS of ypStage III was 61% in AJCC-8th comparing to 51% in AJCC-7th, and that of ypStage IV was 31% in AJCC-8th comparing to 50% in AJCC-7th. Univariate analyses identified ypT-8th (P = 0.028), ypN-8th (P < 0.001), cStage-8th (P = 0.006) and ypStage-8th (P < 0.001) in addition to surgical procedure (P = 0.027) and histological response (P = 0.019) as significant prognostic factors for DSS. Among these, multivariate analysis showed that ypStage-8th was a significant independent prognostic factor for DSS (P < 0.001). Conclusion ypTNM stage grouping in AJCC-8th can more accurately stratify the prognosis of patients who underwent neoadjuvant CF therapy for ESCC, by classifying patients with residual tumor invasion to adjacent structures and regional lymph node metastasis into more unfavorable prognostic group than that in AJCC-7th. ypStage according to AJCC-8th is the most reliable prognosticator for this disease. Disclosure All authors have declared no conflicts of interest.


2018 ◽  
Vol 23 (5) ◽  
pp. 844-850 ◽  
Author(s):  
Satoshi Kano ◽  
Tomohiro Sakashita ◽  
Nayuta Tsushima ◽  
Takatsugu Mizumachi ◽  
Akira Nakazono ◽  
...  

Proceedings ◽  
2019 ◽  
Vol 35 (1) ◽  
pp. 18
Author(s):  
Caponio ◽  
Troiano ◽  
Mascitti ◽  
Santarelli ◽  
Mauceri ◽  
...  

Tongue squamous cell carcinoma (TSCC) accounts for 40% of all squamous cell carcinoma involving the mucosal surface of the oral cavity. TSCC is highly invasive and aggressive and, nowadays, TNM staging system is considered the gold standard in predicting patients’ outcomes. [...]


2019 ◽  
Vol 39 (12) ◽  
Author(s):  
Mei-Di Hu ◽  
Si-Hai Chen ◽  
Yuan Liu ◽  
Ling-Hua Jia

Abstract Background: The present study aimed to develop and validate a nomogram based on expanded TNM staging to predict the prognosis for patients with squamous cell carcinoma of the bladder (SCCB). Methods: A total of 595 eligible patients with SCCB identified in the Surveillance, Epidemiology, and End Results (SEER) dataset were randomly divided into training set (n = 416) and validation set (n = 179). The likelihood ratio test was used to select potentially relevant factors for developing the nomogram. The performance of the nomogram was validated on the training and validation sets using a C-index with 95% confidence interval (95% CI) and calibration curve, and was further compared with TNM staging system. Results: The nomogram included six factors: age, T stage, N stage, M stage, the method of surgery and tumor size. The C-indexes of the nomogram were 0.768 (0.741–0.795) and 0.717 (0.671–0.763) in the training and validation sets, respectively, which were higher than the TNM staging system with C-indexes of 0.580 (0.543–0.617) and 0.540 (0.484–0.596) in the training and validation sets, respectively. Furthermore, the decision curve analysis (DCA) proved that the nomogram provided superior clinical effectiveness. Conclusions: We developed a nomogram that help predict individualized prognosis for patients with SCCB.


Sign in / Sign up

Export Citation Format

Share Document